MediciNova - Worst Pharma Stocks of 2007
Company:Â MediciNova
Starting stock price: $14.00
Ending stock price: $4.6
Percent Change: -67.14%
Details: MediciNova acquires small-molecule drugs from Japanese and other international pharmaceutical companies and accelerates their development. MediciNova currently has eight compounds, six in clinical development, for ten different therapeutic indications. In 2007 the company released results for two of those candidates, MN-221 for Status Asthmaticus and MN-166 for black hole formation in MSÂ patients.
More stories about MediciNova
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: